The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

The high prevalence of depression and anxiety among patients with MBC correlates with diminished survival rates and ...

Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel ...

PFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...